The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer provide essential recommendations for managing carcinoma in situ, invasive breast cancer, Paget’s disease, Phyllodes tumor, inflammatory breast cancer,…

In December 2024 a publication in the Annals of Surgical Oncology analyzed data from the National Cancer Database, showing that HER2 IHC3+ patients had significantly higher pathologic complete response (pCR)…

In the pursuit of improving outcomes for patients with refractory microsatellite-stable metastatic colorectal cancer (MSS mCRC), Dr. Filippo Pietrantonio has made significant contributions through groundbreaking research exploring the potential of combining vorbipiprant, a prostaglandin EP4 antagonist, with PD-1 blockade therapy.

This real-world study sheds light on the clinical outcomes of patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD–TPI). Conducted across Spain and Italy, the study evaluated 26 patients, offering valuable insights into survival outcomes and treatment-related adverse events in routine clinical practice.

The latest SEOM-GEMCAD-TTD clinical guidelines offer comprehensive updates on the adjuvant treatment of colon cancer, emphasizing the importance of personalized therapeutic strategies to optimize patient outcomes. These guidelines provide evidence-based recommendations tailored to tumor stage, molecular characteristics, and patient-specific factors, highlighting the shift towards precision medicine in oncology.

Editor's Note: The European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. At this prestigious conference, Dr. Yanhong Deng from the Sixth Affiliated Hospital, Sun Yat-sen…

Editor's Note: Enhanced Recovery After Surgery (ERAS) has become a core concept in modern perioperative management. By implementing a series of evidence-based optimization measures, ERAS aims to reduce or mitigate…

The 2024 Annual Progress Conference on Clinical Oncology in China (BOC) and Best of ASCO 2024 China (BOC/BOA 2024) was held in Guangzhou. Since 2015, the highly anticipated Annual Progress…

Editor's Note: Since the German scientist Paul Ehrlich introduced the concept of the "magic bullet" in 1913, antibody-drug conjugates (ADCs) have revolutionized cancer treatment, leading to significant breakthroughs and providing…

The MORPHEUS Phase Ib/II trial explores a transformative approach in clinical research by integrating real-world data (RWD) as a hybrid control arm to supplement traditional randomized controlled trials (RCTs) in pancreatic ductal adenocarcinoma (PDAC).